Table 2.
Prevalence of STIs and cervical neoplasia in women from Manhiça, Mozambique.
| n/total | Prevalence (%) | 95% Confidence interval | |
|---|---|---|---|
| Gonococcal infection | 34/250 | 14 | (10; 19) |
| Syphilis (RPR & IgG) | 31/258 | 12 | (8; 17) |
| HPV DNA | 100/253 | 40 | (33; 46) |
| HIV antibodies | 30/256 | 12 | (8; 16) |
| HSV-2 antibodies | 213/257 | 83 | (78; 87) |
| Chlamydia trachomatis | 19/253 | 8 | (5; 11) |
| Trichomona vaginalis | 78/254 | 31 | (25; 37) |
| HBsAg antibodies | 20/255 | 8 | (5; 12) |
| Anti-HBc antibodies | 160/256 | 63 | (56; 68) |
| Any treatable STI* | 128/252 | 51 | (44; 57) |
| Any active STI** | 179/254 | 70 | (64; 76) |
| Cervical neoplasia | 30/245 | 12 | (8; 17) |
*Any treatable STI: syphilis (RPR confirmed by IgG), gonococcal infection, trichomona vaginalis or chlamydia trachomatis.
**Any active STI: syphilis (RPR confirmed by IgG), gonococcal infection, trichomona vaginalis, chlamydia trachomatis, HPV or HIV infection.